Study Published in JAMA Oncology
San Diego – May 11, 2017 – GenomeDx Biosciences, a leader in the field of urologic cancer genomics, today announced that a genomic signature commonly used with breast cancer patients to determine their risk of recurrence has been found to also identify which patients with aggressive prostate cancer may benefit from hormone therapy.
Using gene expression profiles from GenomeDx’s Decipher Genomics Resource Information Database (Decipher GRID®), the study showed that the PAM50 signature can be used in prostate cancer to better predict which men may benefit from early initiation of androgen deprivation therapy (ADT) after surgery, providing a potential clinical tool to personalize prostate cancer treatment. The study, titled “Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy,” was published online this month ahead of print in JAMA Oncology.
“Although prognostic signatures have become widely established in prostate cancer research, the development of signatures that can predict response to individual therapies has been a difficult proposition,” said Felix Feng, M.D., Associate Professor of Radiation Oncology and Urology at the University of California, San Francisco. “The clinical validation of the established breast cancer PAM50 signature for men with prostate cancer will help physicians to predict which patients are most likely to benefit from postoperative hormone therapy, allowing for personalized patient selection, potentially improving treatment outcomes and sparing many patients from unnecessary toxicity.”
The study included clinical and genomic data from 3,782 retrospectively and prospectively collected radical prostatectomy samples in the Decipher GRID, and found that the PAM50 signature had the ability to consistently classify prostate cancer into luminal A, luminal B, and basal-like subtypes. The study determined that luminal B prostate cancers are the most aggressive, with nearly half the patients experiencing metastasis at 10 years. Further, luminal B patients were found to respond better to post-operative ADT, suggesting that these patients should be prioritized for early initiation of hormone therapy.
“Ultimately we envision the field moving towards a biomarker driven approach, whereby prognostic signatures are used to select patients with aggressive disease and predictive signatures are used to select specific therapies,” said Doug Dolginow, M.D., chief executive officer of GenomeDx. “The combination of a genomic test such as Decipher and basal-luminal subtypes could allow for selection of patients who need postoperative ADT, improving the personalization of therapy for patients with prostate cancer.”
About Decipher GRID® and Cancer Classifier Tests
GenomeDx’s Decipher Genomics Resource Information Database (GRID) contains genomic profiles of thousands of tumors from patients with urological cancers, and is believed by GenomeDx to be the largest shared genomic expression database in urologic cancer as well as one of the world’s largest global RNA expression databases using cloud-based analytics. GRID is a platform for interactive research collaboration, and may enable more rapid discovery, development, commercialization and adoption of new genomic solutions for key clinical questions in cancer treatment.
Derived from GRID, GenomeDx’s Decipher Prostate and Bladder Cancer Classifier tests are commercially available genomic tests that provide a genomic assessment of tumor aggressiveness for individual patients. Decipher Biopsy is indicated for men with localized prostate cancer at diagnosis, Decipher Post-Op is indicated for men after prostate removal surgery and Decipher Bladder is indicated for patients being considered for neoadjuvant chemotherapy prior to bladder removal surgery. The Decipher tests are used by physicians to stratify patients into more accurate risk groups than determined by traditional diagnostic tools and to better determine which patients may be more likely to benefit from additional treatment. Each tumor analyzed with a Decipher test adds new data points to the GRID database, which is compiled into a Decipher GRID Profile that may reveal additional biological characteristics of the tumor for ongoing research purposes. Going beyond risk stratification, Decipher and GRID makes accessible genetic information for researchers to potentially better predict responses to therapy and more precisely guide treatment.
About GenomeDx Biosciences
GenomeDx has reimagined the use of genomics as a platform for mass collaboration to improve treatment and outcomes of people with cancer. GenomeDx has built Decipher GRID, a large and fast-growing genomics database in urologic cancer that provides a foundation for open and interactive research collaboration and knowledge creation. Using Decipher GRID and machine learning to analyze vast amounts of genomic data, GenomeDx develops and commercializes proprietary clinical tests that are intended to provide more accurate and useful diagnostic information than traditional diagnostic tools or existing genomic tests. GenomeDx’s Decipher Biopsy, Decipher Post-Op and Decipher Bladder are commercially available urologic cancer genomic tests that provide an assessment of tumor aggressiveness based on a patient’s unique genomic profile. GenomeDx is headquartered in Vancouver, British Columbia and operates a clinical laboratory in San Diego, California.
Learn more at www.GenomeDx.com